New hope for Platinum-Resistant ovarian cancer: Rina-S trial launches
NCT ID NCT07604766
First seen Jun 24, 2026 · Last updated Aug 14, 2026 · Updated 4 times
Summary
This phase 3 trial compares a new drug called Rina-S to standard chemotherapy in 82 people with platinum-resistant ovarian cancer. Participants are randomly assigned to receive either Rina-S or one of four approved chemotherapies. The goal is to see if Rina-S can delay cancer growth better than current treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Rinatabart sesutecan (Rina-S)
- What this could lead to
- If it works, this could offer a new treatment option for people with platinum-resistant ovarian cancer, potentially slowing cancer growth better than current chemotherapies.
- What could go wrong
- This is an early-stage extension study with only 82 participants, so results may not apply to everyone. Rina-S may not prove more effective than existing chemo and could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIOID EPITHELIAL OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chongqing University Cancer Hospital - Chongqing Cancer Hospital
RECRUITINGChongqing, China
-
Fudan University Shanghai Cancer Hospital
RECRUITINGShanghai, China
-
Harbin Medical University Cancer Hospital
RECRUITINGHarbin, China
-
Henan Cancer Hospital
RECRUITINGZhengzhou, China
-
Hunan Cancer Hospital
RECRUITINGChangsha, China
-
Liaoning Cancer Hospital
RECRUITINGShenyang, China
-
Nanjing Drum Tower Hospital (The Affiliated Hospital of Nanjing University Medical School)
RECRUITINGNanjing, China
-
Obstetrics & Gynecology Hospital of Fudan University
RECRUITINGShanghai, China
-
Shandong First Medical University Affiliated Tumor Hospital
RECRUITINGJinan, China
-
Shanxi Cancer Hospital
RECRUITINGTaiyuan, China
-
Sun Yat-Sen Memorial Hospital
RECRUITINGGuangzhou, China
-
Sun Yat-Sen University Cancer Center
RECRUITINGGuangzhou, China
-
The First Affiliated Hospital of Xi'an Jiaotong University
RECRUITINGXi'an, China
-
The First Hospital of Jilin University
RECRUITINGChangchun, China
-
Tianjin Medical University Cancer Institute & Hospital
RECRUITINGTianjin, China
-
West China Second University Hospital, Sichuan University
RECRUITINGChengdu, China
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a custom vaccine train the body to fight ovarian cancer?
- Can a 'Smart Bomb' drug outsmart recurrent ovarian cancer?
- Can a targeted drug boost standard ovarian cancer therapy?
- Can heated chemo during surgery help older women with ovarian cancer?
- Can a daily pill keep BRCA-Linked ovarian cancer at bay?
- New drug cocktail aims to shrink recurrent ovarian tumors